Jingting Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingting Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chaoyang Zhang
Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications Dawei Luo
Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital) Shanghai Jiao Tong University Shanghai China
2 shared publications- Hai Xie
Department of Ophthalmology of Shanghai Tenth People's Hospital, Tongji Eye Institute Tongji University School of Medicine Shanghai China
2 shared publications - Jingfa Zhang
The Primasia International Eye Research Institute, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China
2 shared publications - Kun Liu
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Qinghua Qiu
Department of Ophthalmology, Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- 13 October 2021
- Published by Wiley in Cell Biology International
- Vol. 46 (1) , 129-138
An in vitro cell model to study microglia activation in diabetic retinopathy
Microglial activation has been studied extensively in diabetic retinopathy. We have previously detected activation and migration of microglia in 8‐week‐old diabetic rat retinas. It is widely acknowledged that microglia‐mediated inflammation contributes to the progression of diabetic retinopathy. However, existing cell models do not explore the role of activated microglia in vitro. In this study, microglia were subject to various conditions mimicking diabetic retinopathy, including high glucose, glyoxal, and hypoxia. Under high glucose or glyoxal treatment, microglia demonstrated only partially functional changes, while under hypoxia, microglia became fully activated showing enlarged cell bodies, enhanced migration and phagocytosis as well as increased production of pro‐inflammatory factors such as cyclooxygenase‐2 (COX‐2), interleukin‐1β (IL‐1β), and inducible nitric oxide synthase (iNOS). The data indicate that hypoxia‐treated microglia is an optimal in vitro model for exploration of microglia activation in diabetic retinopathy.
- 13 October 2021
- Published by Wiley in Cell Biology International
- Vol. 46 (1) , 129-138
An in vitro cell model to study microglia activation in diabetic retinopathy
Microglial activation has been studied extensively in diabetic retinopathy. We have previously detected activation and migration of microglia in 8‐week‐old diabetic rat retinas. It is widely acknowledged that microglia‐mediated inflammation contributes to the progression of diabetic retinopathy. However, existing cell models do not explore the role of activated microglia in vitro. In this study, microglia were subject to various conditions mimicking diabetic retinopathy, including high glucose, glyoxal, and hypoxia. Under high glucose or glyoxal treatment, microglia demonstrated only partially functional changes, while under hypoxia, microglia became fully activated showing enlarged cell bodies, enhanced migration and phagocytosis as well as increased production of pro‐inflammatory factors such as cyclooxygenase‐2 (COX‐2), interleukin‐1β (IL‐1β), and inducible nitric oxide synthase (iNOS). The data indicate that hypoxia‐treated microglia is an optimal in vitro model for exploration of microglia activation in diabetic retinopathy.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Imaging Hyperreflective Foci as an Inflammatory Biomarker after Anti‐VEGF Treatment in Neovascular Age‐Related Macular Degeneration Patients with Optical Coherence Tomography Angiography
Purpose. To investigate the hyperreflective foci (HRF) as an inflammatory biomarker using optical coherence tomography angiography (OCTA) in neovascular age‐related macular degeneration (AMD) patients after antivascular endothelial growth factor (anti‐VEGF) treatment and its association with the retinal microcapillary density. Methods. Twenty‐five eyes from 25 patients with neovascular AMD were included in the study. All eyes were imaged with OCTA at baseline (M0) and after 3 consecutive injections (M3; injection performed each month) of anti‐VEGF. The number of HRF in the superficial capillary plexus (SCP), deep capillary plexus (DCP), and outer retina was counted. The vascular density of the fovea, parafovea, and the whole macula, as well as the area of the foveal avascular zone (FAZ), was measured. Results. The mean interval between baseline and follow‐up with OCTA was 93.08 ± 5.00 (range, 85‐101) days. Compared with the baseline, the number of HRF significantly decreased in DCP (7.52 ± 3.06 vs. 3.76 ± 1.48, P < 0.01) and outer retina (12.04 ± 4.91 vs. 5.88 ± 3.32, P < 0.01) after treatment. There was no significant difference for HRF number in the SCP, the vascular density (containing foveal, parafoveal, and whole macular), and FAZ area before and after treatments. Conclusion. The number of HRF in DCP and outer retina might serve as an inflammatory biomarker in patients with neovascular AMD. The reduced HRF possibly represents the alleviation of inflammation after anti‐VEGF treatment in patients with AMD.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessImaging Hyperreflective Foci as an Inflammatory Biomarker after Anti‐VEGF Treatment in Neovascular Age‐Related Macular Degeneration Patients with Optical Coherence Tomography Angiography
Purpose. To investigate the hyperreflective foci (HRF) as an inflammatory biomarker using optical coherence tomography angiography (OCTA) in neovascular age‐related macular degeneration (AMD) patients after antivascular endothelial growth factor (anti‐VEGF) treatment and its association with the retinal microcapillary density. Methods. Twenty‐five eyes from 25 patients with neovascular AMD were included in the study. All eyes were imaged with OCTA at baseline (M0) and after 3 consecutive injections (M3; injection performed each month) of anti‐VEGF. The number of HRF in the superficial capillary plexus (SCP), deep capillary plexus (DCP), and outer retina was counted. The vascular density of the fovea, parafovea, and the whole macula, as well as the area of the foveal avascular zone (FAZ), was measured. Results. The mean interval between baseline and follow‐up with OCTA was 93.08 ± 5.00 (range, 85‐101) days. Compared with the baseline, the number of HRF significantly decreased in DCP (7.52 ± 3.06 vs. 3.76 ± 1.48, P < 0.01) and outer retina (12.04 ± 4.91 vs. 5.88 ± 3.32, P < 0.01) after treatment. There was no significant difference for HRF number in the SCP, the vascular density (containing foveal, parafoveal, and whole macular), and FAZ area before and after treatments. Conclusion. The number of HRF in DCP and outer retina might serve as an inflammatory biomarker in patients with neovascular AMD. The reduced HRF possibly represents the alleviation of inflammation after anti‐VEGF treatment in patients with AMD.